

**Bristol-Myers Squibb Company**  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
Telephone: (609) 252-6385  
Fax: (609) 252-4526

**FACSIMILE TRANSMISSION**

**To:** Examiner R. L. Anderson  
U.S.P.T.O.

**Date:** September 11, 2003

**Fax No.:** (703) 746-7444

**cc:**

**From:** Terence J. Bogie

**Pages:** 12 (including cover)

---

THIS FACSIMILE CONTAINS PRIVILEGED OR CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S). EXCEPT FOR DELIVERY TO THE INTENDED RECIPIENT, ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS.

---

**Re: Supplemental Response to Advisory Action of September 2, 2003**  
USSN 10/027,982  
Our Reference: QA0238 NP


Examiner Anderson:

Thank you for speaking with me on Wednesday, September 10, 2003, regarding the above-identified case. As per our conversations of September 10, 2003, the claims have been amended to further clarify subject matter that the applicants believe meets the statutory requirements for allowance.

If you have any questions or this facsimile is illegible, please do not hesitate to contact me at the telephone number set forth above.


Thank you for your assistance in this matter.

Sincerely,



Terence Bogie  
Attorney for the Applicants

CASE QA0238 NP

CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 746-7444 on September 11, 2003.	
Terence J. Bogle Type or print name	 Signature

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
BARRISH ET AL.

Art Unit: 1626

Examiner: Rebecca L. Anderson

APPLICATION NO: 10/027,982

FILED: DECEMBER 20, 2001

FOR: THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

Fee calculation:

Multiple Dependent Claims (\$ 280)							\$
For	Number Presented	Number Prev. Paid	Number Extra		Rate		
TOTAL CLAIMS	11	- 22	= 0	x	\$ 18	=	\$ 0
INDEPENDENT CLAIMS	1	- 3	= 0	x	\$ 84	=	\$ 0
TOTAL FEE							\$ 0


- ☒ No additional fee is required. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17, which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

(609) 252-6385

Date: September 11, 2003

  
Terence J. Bogie  
Attorney for Applicants  
Registration No. 44,544

CASE QA0238 NP

<b><u>CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)</u></b>	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 746-7444 on September 11, 2003.	
Terence J. Bogie Type or print name	 Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

BARRISH ET AL.

Examiner: Rebecca L. Anderson

APPLICATION NO: 10/027,982

FILED: DECEMBER 20, 2001

FOR: THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE  
KINASES

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL RESPONSE TO ADVISORY ACTION**

Sir:

Applicants are appreciative of the time afforded them by the Examiner in helping identify subject matter within the pending claims of the above-identified patent application that meets statutory requirements for allowance. This response is directed at that subject matter, and is provided in response to telephone conversations that applicants' attorney had with the Examiner on September 10, 2003.

Applicants respectfully request that the above-identified patent application be amended, without prejudice, as follows:

**Amendments to the Claims** are reflected in the amendments in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.